Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival
- 1Memorial Sloan Kettering Cancer Center, New York, New York.
- 2Howard Hughes Medical Institute, Chevy Chase, Maryland.
Abstract
Real-world data suggest that SARS-CoV-2 mRNA vaccines, administered within 100 days of immune checkpoint inhibitor (ICI) treatment (“peri-ICI vaccination”), may improve ICI effectiveness through synergistic immune priming. In an independent real-world cohort and reanalysis of a published cohort, both from tertiary cancer centers in the United States, multiple analyses did not support a treatment-synergy hypothesis. Applying a prior analytic framework, although longer survival with peri-ICI vaccination was observed at the start of the pandemic, this association was not seen in periods when vaccination was broadly available. Longer survival with vaccination in the early pandemic was also not specific to ICI therapies. Progression-free survival during periods of high vaccine uptake was not longer than in prevaccination periods. Together, these findings indicate that the previously reported vaccination survival advantage is largely explained by selection bias, with patients who had more favorable prognoses more likely to receive the SARS-CoV-2 vaccination, particularly in the early pandemic.
Significance:: The impact of tumor antigen–agnostic vaccination on immunotherapy response is unclear. In a reanalysis of published data and in an independent cohort, after adjustment for multiple confounders, SARS-CoV-2 mRNA vaccination did not improve immunotherapy-related survival in patients with cancer.
Related
- Exploring tumor-derived exosomes as promising antigenic platforms: novel vaccine and immunotherapy strategies for “cold” colorectal cancer
- Trained immunity in cancer immunotherapy and vaccine development: mechanisms, evidence gaps, and translational opportunities
- Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma
- Cyclic-thiourea ionizable lipids program multilamellar mRNA-LNPs for sustained expression, frozen-storage stability and potent vaccine immunotherapy
- Long non-coding RNA prompts immune-related adverse events risk and immunotherapy response in pan-cancer
BibTeX
@article{jee2026deconvolving,
title = {{Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival}},
author = {Justin Jee and Jiajia Zhang and Jessica A. Lavery and Michele Waters and Christoper J. Fong and Andy J. Minn and Michael S. Glickman and Katherine S. Panageas and Charles L. Sawyers and Nikolaus Schultz},
journal = {Cancer Discovery},
year = {2026},
month = jun,
doi = {10.1158/2159-8290.cd-26-0403},
url = {https://doi.org/10.1158/2159-8290.cd-26-0403},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival
AU - Justin Jee
AU - Jiajia Zhang
AU - Jessica A. Lavery
AU - Michele Waters
AU - Christoper J. Fong
AU - Andy J. Minn
AU - Michael S. Glickman
AU - Katherine S. Panageas
AU - Charles L. Sawyers
AU - Nikolaus Schultz
PY - 2026
DA - 2026/06/22
JO - Cancer Discovery
DO - 10.1158/2159-8290.cd-26-0403
UR - https://doi.org/10.1158/2159-8290.cd-26-0403
AB - Real-world data suggest that SARS-CoV-2 mRNA vaccines, administered within 100 days of immune checkpoint inhibitor (ICI) treatment (“peri-ICI vaccination”), may improve ICI effectiveness through synergistic immune priming. In an independent real-world cohort and reanalysis of a published cohort, both from tertiary cancer centers in the United States, multiple analyses did not support a treatment-synergy hypothesis. Applying a prior analytic framework, although longer survival with peri-ICI vaccination was observed at the start of the pandemic, this association was not seen in periods when vaccination was broadly available. Longer survival with vaccination in the early pandemic was also not specific to ICI therapies. Progression-free survival during periods of high vaccine uptake was not longer than in prevaccination periods. Together, these findings indicate that the previously reported vaccination survival advantage is largely explained by selection bias, with patients who had more favorable prognoses more likely to receive the SARS-CoV-2 vaccination, particularly in the early pandemic. Significance:: The impact of tumor antigen–agnostic vaccination on immunotherapy response is unclear. In a reanalysis of published data and in an independent cohort, after adjustment for multiple confounders, SARS-CoV-2 mRNA vaccination did not improve immunotherapy-related survival in patients with cancer.
SN - 2159-8274
SN - 2159-8290
ER -